financetom
Business
financetom
/
Business
/
Update: POET Technologies Jumps 9.4% as it Collaborates with Foxconn Interconnect Technology for High-Speed AI Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: POET Technologies Jumps 9.4% as it Collaborates with Foxconn Interconnect Technology for High-Speed AI Systems
May 14, 2024 9:01 AM

11:34 AM EDT, 05/14/2024 (MT Newswires) -- POET Technologies ( POET ) said Tuesday that it agreed to collaborate with Foxconn Interconnect Technology (FIT) to develop 800G and 1.6T pluggable optical transceiver modules using POET's optical engines.

The partnership aims to address growing demand from cutting-edge AI applications and high-speed data center networks, POET said.

As part of the collaboration, POET said it will develop and supply its silicon photonics integrated-circuit optical engines based on the patented POET Optical Interposer technology and FIT.

POET expects to complete the design of the optical engines for FIT by the third quarter and start optical engine production at its joint venture, Super Photonics Xiamen, by the fourth quarter.

POET shares were last seen up $0.28 to $3.27 on the TSX Venture Exchange.

Price: 3.27, Change: +0.28, Percent Change: +9.36

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roblox Lifts 2025 Bookings Outlook, Flags Margin Pressures Amid Higher Spending
Roblox Lifts 2025 Bookings Outlook, Flags Margin Pressures Amid Higher Spending
Oct 30, 2025
02:05 PM EDT, 10/30/2025 (MT Newswires) -- Roblox ( RBLX ) raised its full-year bookings guidance, while the video game platform flagged potential margin pressures from increased investments in infrastructure and people. For fiscal 2025, the company now expects bookings of $6.57 billion to $6.62 billion, representing growth of 50% to 51% year over year, up from its prior outlook...
AstraZeneca Gefurulimab Shows Positive Phase 3 Results in Myasthenia Gravis Trial
AstraZeneca Gefurulimab Shows Positive Phase 3 Results in Myasthenia Gravis Trial
Oct 30, 2025
02:01 PM EDT, 10/30/2025 (MT Newswires) -- AstraZeneca ( AZN ) reported positive results from its Phase 3 trial of gefurulimab, showing statistically significant and clinically meaningful improvements in patients' ability to perform daily activities with generalized Myasthenia Gravis, a chronic autoimmune neuromuscular disorder. The trial met its primary endpoint, demonstrating a significant improvement in the Myasthenia Gravis Activities of...
--Louisiana-Pacific Keeps Quarterly Dividend at $0.28 a Share, Payable Nov. 21 to Holders of Record Nov. 14
--Louisiana-Pacific Keeps Quarterly Dividend at $0.28 a Share, Payable Nov. 21 to Holders of Record Nov. 14
Oct 30, 2025
02:10 PM EDT, 10/30/2025 (MT Newswires) -- Price: 89.32, Change: +0.23, Percent Change: +0.26 ...
Abeona Therapeutics Gets Permanent CMS J-Code for Zevaskyn Gene Therapy
Abeona Therapeutics Gets Permanent CMS J-Code for Zevaskyn Gene Therapy
Oct 30, 2025
02:10 PM EDT, 10/30/2025 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Thursday its autologous gene therapy Zevaskyn received a permanent Healthcare Common Procedure Coding System J-code from the Centers for Medicare and Medicaid Services. The new product-specific identifier, J3389 - Topical administration, prademagene zamikeracel, per treatment - will take effect on Jan. 1, 2026, the company added. Zevaskyn...
Copyright 2023-2026 - www.financetom.com All Rights Reserved